Radio and PodcastRadio and PodcastLive Radio & Podcasts
BR.31 & Asco GU '26 artwork
Science & Medicine

BR.31 & Asco GU '26

OncoPharm by OncoPharmPod

Mar 5, 202600:18:00Science & Medicine

This week discuss BR.31 trial of adjuvant durvalumab in NSCLC and put it into the context of the positive studies with atezolizumab and pembrolizumab. We also highlight 2 notable presentations at ASCO GU 2026 on perioper...

About This Episode

BR.31 & Asco GU '26 is an episode from OncoPharm by OncoPharmPod. This week discuss BR.31 trial of adjuvant durvalumab in NSCLC and put it into the context of the positive studies with atezolizumab and pembrolizumab. We also highlight 2 not...

Podcast

This episode belongs to OncoPharm.

Listen Online

Use the player on this page to stream the episode online.

Episode Details

Published Mar 5, 2026, 00:18:00 long, audio available.

Related Episodes

Continue listening to more episodes from OncoPharm.

IMHOTEP, PJP, and more

May 14, 2026 - 00:09:59

This week's pod has lots of updates! IMHOTEP: Pre-operative doses of pembrolizumab lead to significant pC...

Vepdegestrant

May 7, 2026 - 00:11:35

The latest FDA drug approval is vepdegestrant, a heterobifunctional protein degrader, for ESR1 mutated br...

Targets Trop 2

Apr 30, 2026 - 00:12:41

This is our 1st in a series of podcasts/videos to role out once or twice a year on therapeutic targets in...

Promising Pancreatic Cancer Data

Apr 23, 2026 - 00:13:56

This week we highlight some promising clinical research in the pancreatic cancer space. Daraxonrasib has...

ICI-Induced T1DM

Apr 16, 2026 - 00:13:24

Bibliography: 1.. 2019 Systematic Review of Published Cases: 2. Mass General Data & Publication: 3. Japan...

Relacorilant

Apr 9, 2026 - 00:15:13

Discussing the new nab-paclitaxel adjunctive medication, relacorilant, for ovarian cancer. As a glucoCORt...

HOPA 2026 Recap

Apr 2, 2026 - 00:13:36

Recapping what I learned at HOPA 2026: -Beyond steroids for irAs -IT chemo beyond methotrexate and cytara...

Nivo-AVD Approval

Mar 24, 2026 - 00:09:32

Nivolumab-AVD is finally approved for Hodgkin Lymphoma, and primary G-CSF prophylaxis is recommended (?)...

Questions About This Episode

What is BR.31 & Asco GU '26 about?

This week discuss BR.31 trial of adjuvant durvalumab in NSCLC and put it into the context of the positive studies with atezolizumab and pembrolizumab. We also highlight 2 notable presentations at ASCO GU 2026 on perioperative enfortumab vedotin + pembrolizumab in cisplatin-eligible patients with resectable bladder cancer (KEYNOTE-B15) and advjuant pembrolizumab + belzutifan in RCC (LITESPARK-022) Check out the Oncology Insights Newsletter:

Where can I listen to BR.31 & Asco GU '26?

You can listen to BR.31 & Asco GU '26 online on Radio and Podcast. Open the player on this page to stream the available audio.

Which podcast is BR.31 & Asco GU '26 from?

BR.31 & Asco GU '26 is an episode from OncoPharm by OncoPharmPod.

How long is this episode?

This episode is 00:18:00 long.

When was this episode published?

This episode was published on Mar 5, 2026.

Can I save BR.31 & Asco GU '26 for later?

Yes. Use the heart button on the episode page to add it to your favorite episodes list.

Are there related episodes from OncoPharm?

Yes. This page shows related episodes from OncoPharm when more episodes are available from the podcast feed.